PD-1/PD-L1-IN-9

PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC 50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model In Vitro PD-1/PD-L1-IN-9 (compound 24) (46.9-1500 nM; pretreated for 2 h) dose-dependently significantly activates the antitumor immunity of peripheral blood mononuclear cells (PBMCs) to MDB-MB 231 cells, with an EC 50 of ∼100 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo PD-1/PD-L1-IN-9 (compound 24) (40-80 mg/kg; p.o.; once a day for 2 weeks) inhibits tumor growth in a dose-dependent manner and does not cause any body weight loss or mortality of mice . PD-1/PD-L1-IN-9 (3 mg/kg; i.v.; single dose) exhibits half-life (T 1/2 =4.2 h), plasma clearance (Cl=11.5 L/h/kg) and C max (1233 ng/mL) in rats . PD-1/PD-L1-IN-9 (25 mg/kg; p.o.; single dose) exhibits moderate oral bioavailability (F=22 %), half-life (t 1/2 =6.4 h) and C max (192 ng/mL) in rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male BALB/c mice (5-6 weeks) were inoculated CT26 cells Dosage: 40 mg/kg, 80 mg/kg Administration: Oral gavage; once daily, for 2 weeks Result: Significantly decreased the final tumor weight, with TGI values of 60 and 67% at the dose of 40 and 80 mg/kg, respectively. Animal Model: Pharmacokinetic analysis in sprague-Dawley (SD) rats Dosage: 3 mg/kg and 25 mg/kg Administration: Intravenous injection or oral gavage; single dose Result: Route Dose (mg/kg) AUC (0-t) (ng·h/mL) C max (ng/mL) t 1/2 (h) T max Cl (L·h/kg) V z (L/kg) F (%) i.v. 3 430.5 1233 4.2 0.03 11.5 78.6 / p.o. 25 787.4 192 6.4 0.69 28.8 249.3 22 Form:Solid IC50& Target:IC50: 3.8 nM (PD-1/PD-L1)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet